Skip to content

About Us
- About Us
- Team
- Careers
- Investors
- Collaborations
Our Technology
- Our Technology
- Our Device
Pipeline
News
Contact Us

Menu

About Us
- About Us
- Team
- Careers
- Investors
- Collaborations
Our Technology
- Our Technology
- Our Device
Pipeline
News
Contact Us

News

August 30, 2022

Santersus AG in combination with their institutional partners our extremely proud to present the newest findings regarding the success in the Ex Vivo lung perfusion studies.

REMOVAL-OF-NEUTROPHIL-EXTRACELLULAR Download

Related links

About Santersus

https://www.santersus.com/

About VolitionRx Limited

https://www.volition.com/

If you would like to learn more about our technology, please contact Santersus team at info@santersus.com

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

September 16, 2026

Santersus AG Appoints New Chief Executive Officer and Expands Board of Directors

December 11, 2025

Santersus AG Completes Series A Financing led by Norcliffe Capital, joined by Terumo Ventures, and Announces Strategic Collaboration with Terumo Corporation and Advancement of NucleoCapture into Pivotal Clinical Development

December 1, 2025

Santersus AG Congratulates OrganOx on Strategic Acquisition by Terumo Corporation — Underscores Ongoing Collaboration in Donor Liver Perfusion

September 13, 2025

Santersus AG Receives Second U.S. FDA Breakthrough Device Designation for NucleoCapture™ in Systemic Lupus Erythematosus

August 27, 2025

Page1 Page2 Page3 Page4 Page5

CONTACT US

SANTERSUS AG c/o Lex Futura AG Nüschelerstrasse 45 8001 Zürich Switzerland

+ 41 44 586 3656
info@santersus.com

LEGAL

View our full disclaimer